Status: Recruiting
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).
Participants needed: 148
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Methodist Hospital Research InstituteUpdated: Mar 12, 2026Locations: 1
Eligibility criteria
Signed informed consent form. [+15]
Difficulty or inability to hear and/or understand loud speech and sounds. [+10]